Robert F. Kennedy Jr. has been vocal about his intentions concerning the regulation of peptides, and it appears he is now taking decisive action.
The recent developments indicate that Kennedy's long-anticipated initiatives are finally coming to fruition, potentially reshaping the landscape of FDA oversight.
As the situation evolves, the implications of these changes for the healthcare and pharmaceutical sectors will need to be closely monitored.